Lymphopoiesis of B-lineage cells is a complex process requiring stage-specific expression of multiple surface and cytoplasmic proteins that contribute to development and function. This complex process comprises biological progression from a lymphoid progenitor cell to a terminally differentiated plasma cell. Each step in this normal biological progression also has a malignant counterpart either referred to as leukemia or lymphoma (Figure 1a and b). 1 The neutral endopeptidase 24.11, (NEP or CD10), is considered a regulator of B-cell growth and proliferation. 2 The enzyme is a cell surface aminopeptidase capable of degrading a number of bioactive peptides with various functions that depend on the cell type or tissue of origin and is active in early bone marrow (BM) precursor B cells and lymph node germinal center (GC) B cells. In addition, CD10 is expressed in malignancies including precursor B cell acute lymphocytic leukemia (B-ALL), GC-related non-Hodgkin's lymphoma (NHL) such as Burkitt's lymphoma and follicular lymphoma (FL), and GC-related diffuse large B-cell lymphomas (DLBCL). It is not, however, expressed in terminally differentiated plasma cells of multiple myeloma (MM), in the pre-GC cells of mantle cell lymphoma (MCL), or in the pre-or post-GC cells of B-cell chronic lymphocytic leukemia (B-CLL). Thus, there is a biphasic pattern of CD10 cell surface protein expression that correlates with specific stages of development in both normal and neoplastic B cells and precursor B cells (Figure 1c) .
The development of lymphoid malignancies involves the acquisition of a series of genetic and epigenetic alterations that give the cell a selective growth advantage. One cancer-related epigenetic alteration, gene promoter DNA methylation, occurs at cytosines within CG dinucleotides frequently clustered into cytosine-phosphate-guanosine (CpG) islands (reviewed by Laird 3 ). When CpG sites within a promoter CpG island are predominately methylated, there is frequently little or no expression of the associated gene. 4 Accumulating evidence indicates that abnormal DNA methylation of promoter and first Letters to the Editor exon CpG islands have profound effects on tumorigenesis. In fact, a number of individual genes have been reported as silenced in B-ALL and NHL with known roles in a variety of cellular processes suggesting that CpG island methylation is important in the genesis and clinical behavior of these malignancies.
An inverse correlation was previously observed between methylation of the CD10 promoter and CD10 expression in B-ALL. 5 In order to extend these studies we investigated CD10 methylation and protein expression across a spectrum of normal and malignant B cells (including B-ALL). This was intended to gain further insights into the potential regulation and/or clinical significance of CD10 expression and gene promoter methylation in this spectrum of B-cell malignancies and their normal counterparts.
In compliance with Institutional Review Board guidelines, BM and lymph node specimens were freshly obtained from patients undergoing diagnostic evaluation for suspected acute leukemia or lymphoma. The presence of cell surface CD10 expression was determined by multicolor flow cytometry. 6 DNA was isolated from a total of 82 malignant cases, including B-ALL (n ¼ 10), B-CLL/small lymphocytic lymphoma (SLL) (n ¼ 27; 12 CD38 þ , 15 CD38À), MCL (n ¼ 5), FL (n ¼ 18), DLBCL (n ¼ 16) and MM (n ¼ 6). All malignant specimens contained a minimum of 80% neoplastic cells, as determined by flow cytometry (data not shown). We included 23 non-malignant specimens consisting of three individual and one pool of female peripheral blood leukocytes (PBL), two individual and one pool of male PBL, four BM, 11 benign follicular hyperplasia and one sample consisting of purified CD19 þ B cells. Enrichment of B cells was accomplished by magnetic immunoseparation into CD19 þ and CD19-lymph node cells; CD19 þ lymph node cells were then further immunoseparated to yield a population of CD19 þ / CD77 þ GC B cells. This method routinely yields 495% purity and 485% recovery in our laboratory.
We first used combined bisulfite restriction analysis (COBRA) to determine the methylation status within the CD10 promoter (Figure 1d ) of the 82 B-ALL and NHL cases representing various stages of differentiation. Bisulfite treatment of genomic DNA was performed with the EZ DNA Methylation Kit (Zymo Research, Orange, CA, USA). After treatment, the DNA was used as a template for polymerase chain reaction (PCR) amplification using primers and conditions as described previously. 7 Of the least differentiated malignancies, the 10 B-ALL cases examined, 6/10 (60%) were CD10 þ , none of which demonstrated DNA methylation. Of the four CD10À cases, promoter DNA methylation was present in two (50%). Of the more mature NHLs, B-CLL/SLL comprises both a pre-GC and a post-GC stage of differentiation on the basis of immunoglobulin heavy chain variable region genes, expression of CD38 and of ZAP-70. 1 We thus investigated whether CD10 promoter methylation was present in B-CLL/SLL and whether it correlated with CD38 expression as a surrogate of subtype. None of the 27 CLL cases expressed CD10, and 37% (10/27) of these demonstrated promoter methylation (6/15 CD38À; 4/12 CD38 þ ). However, there was no correlation between methylation status and CD38 expression. In the MCL, FL and DLBCL cases negative for CD10 expression, 40% (2/5), 33% (1/3) and 42% (5/12) demonstrated CD10 promoter DNA methylation, respectively. Conversely, of the 15 CD10 þ FL and four DLBCL, none (0/15 and 0/4) exhibited CD10 methylation. All six MM cases failed to express CD10, as expected, and none of these exhibited promoter DNA methylation. Overall, we observed a reciprocal correlation between promoter DNA methylation and CD10 expression in the primary tumor samples (Figure 1c, d) . When CD10 was expressed (n ¼ 25), only one (4%) case (FL) demonstrated promoter methylation. In the absence of CD10 expression (n ¼ 57), 21 cases (37%) revealed CD10 methylation. Thus, although a correlation was present, it was not absolute. To determine if this reciprocal relationship was present in non-malignant cells, we analyzed normal samples encompassing the spectrum of differentiating B cells which were all negative for promoter DNA methylation regardless of CD10 protein expression (data not shown).
We also studied three B-ALL and five NHL cell lines covering the spectrum of putative maturation stages of B-cell malignancies for CD10 methylation and protein expression as determined by flow cytometry. The immature B-ALL cell lines, MN-60 and NALM6 expressed CD10 whereas SD-1 did not. The mature Raji and Daudi cell lines are GC-derived Burkitt's lymphoma cell lines and express CD10. The GC cell line RL is a FL derived from a male patient with the t(14;18) translocation and expresses CD10. DB is a post-GC derived DLBCL cell line and expresses CD10. Mec-1 is a pre-GC (CD38 þ ) derived CLL cell line and does not express CD10. Cells from all eight cell lines were harvested and DNA was isolated using DNeasy Tissue Prep Kit (Qiagen, Valencia, CA, USA) for use in COBRA methylation analysis. In the three B-ALL cell lines, none demonstrated CD10 promoter methylation, but two (MN-60 and NALM6) expressed the CD10 protein. The SD-1 cell line was unmethylated but still failed to express the protein. Of the five NHL cell lines, the CD10 promoter was methylated and the protein was not expressed in Mec-1, a CLL cell line, whereas in the remaining four cell lines (Raji, Daudi, RL and DB) CD10 was expressed and no promoter DNA methylation was detected. These results are consistent with those from the primary patient samples.
To determine if CD10 mRNA expression could be restored in vitro after epigenetic treatment, the Mec-1 CLL cell line that was methylated and failed to express CD10, was treated with 5-AZA and trichostatin A (TSA) alone and in combination. CD10 mRNA expression was not re-established in the cell cultures treated with 5-AZA or TSA alone. However, expression was restored by culturing with a combination of 5-AZA and TSA (data not shown). This suggests that methylation alone is not likely to control CD10 expression in this cell line and that a synergistic effect of demethylation and re-acetylation is required for the restoration of CD10 mRNA expression.
Despite the importance of DNA methylation in cancer, very few studies have analyzed in vivo the relationship between DNA methylation and protein expression. This is important, as obviously DNA methylation is not the only mechanism that controls gene expression. This study illustrates the inverse association between CD10 methylation and cell surface protein expression across the spectrum of malignant B-cell differentiation. However, this was not absolute; not all CD10 þ tumors lacked methylation and not all CD10À tumors exhibited methylation.
Our results also demonstrated that the CD10 promoter region studied is consistently unmethylated in normal lymphocytes at early and late stages of maturation regardless of the level of CD10 expression. This suggests that expression in normal B-cell differentiation is not controlled by DNA methylation of the CD10 promoter. Although we also observed the expected biphasic expression of CD10 across the spectrum of B-cell malignancies, unlike their normal counterparts, we found that methylation of the CD10 promoter was common at specific stages and was frequently associated with an absence of CD10 expression. Conversely, many cases that did express CD10 showed no methylation, but this was not absolute. This suggests that CD10 methylation might play a role in lymphoid malignancies by silencing CD10 expression, but this does not occur in all cases, and in fact does not prove a cause and effect relationship. Results of this study suggest that the biphasic pattern of CD10 expression in normally differentiating B cells is not controlled by methylation of the CD10 promoter. The expression of CD10 in Mec1 cells is restored after treatment with the combination of a demethylating agent and a histone deacetylase inhibitor, but neither alone; this suggests epigenetic modifications in the silencing of CD10 in this cell line and perhaps in B-cell malignancies, but requires further investigations for complete elucidation.
